Abstract:Organoids, characterized by their high physiological attributes, effectively preserve the genetic characteristics, physiological structure, and function of the simulated organs. Since the inception of small intestine organoids, other organoids for organs including the liver, lungs, stomach, and pancreas have subsequently been developed. However, a comprehensive summary and discussion of research findings on gastrointestinal tract (GIT) organoids as disease models and drug screening platforms is currently lacking. Herein, in this review, we address diseases related to GIT organoid simulation and highlight the notable advancements that have been made in drug screening and pharmacokinetics, as well as in disease research and treatment using GIT organoids. Organoids of GIT diseases, including inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and Helicobacter pylori infection, have been successfully constructed. These models have facilitated the study of the mechanisms and effects of various drugs, such as metformin, Schisandrin C, and prednisolone, in these diseases. Furthermore, GIT organoids have been used to investigate viruses that elicit GIT reactions, including Norovirus, SARS-CoV-2, and rotavirus. Previous studies by using GIT organoids have shown that dasabuvir, gemcitabine, and imatinib possess the capability to inhibit viral replication. Notably, GIT organoids can mimic GIT responses to therapeutic drugs at the onset of disease. The GIT toxicities of compounds like gefitinib, doxorubicin, and sunset yellow have also been evaluated. Additionally, these organoids are instrumental for the study of immune regulation, post-radiation intestinal epithelial repair, treatment for cystic fibrosis and diabetes, the development of novel drug delivery systems, and research into the GIT microbiome. The recent use of conditioned media as a culture method for replacing recombinant hepatocyte growth factor has significantly reduced the cost associated with human GIT organoid culture. This advancement paves the way for large-scale culture and compound screening of GIT organoids. Despite the ongoing challenges in GIT organoid development (e.g., their inability to exist in pairs, limited cell types, and singular drug exposure mode), these organoids hold considerable potential for drug screening. The use of GIT organoids in this context holds great promises to enhance the precision of medical treatments for patients living with GIT diseases.

Generation of cynomolgus monkey airway, liver ductal, and kidney organoids with pharmacokinetic functions

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

High-throughput "Read-on-ski" Automated Imaging and Label-Free Detection System for Toxicity Screening of Compounds Using Personalised Human Kidney Organoids.

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

The establishment of kidney cancer organoid line in drug testing

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Kidney Organoid and Microphysiological Kidney Chip Models to Accelerate Drug Development and Reduce Animal Testing

Drug screening model meets cancer organoid technology

Advancing preclinical drug evaluation through automated 3D imaging for high-throughput screening with kidney organoids

Gastrointestinal tract organoids as novel tools in drug discovery

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform

Organoids: A new approach in toxicity testing of nanotherapeutics

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Drug cytotoxicity screening using human intestinal organoids propagated with extensive cost-reduction strategies

Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver

The application of pancreatic cancer organoids for novel drug discovery

Kidney organoids as a promising tool in nephrology

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Validating Well-Functioning Hepatic Organoids for Toxicity Evaluation

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening